PLSE - Pulse Biosciences, Inc.
| Previous Close | 6.36 |
| Open | 6.29 |
| Bid | 6.56 x 1000 |
| Ask | 6.67 x 1300 |
| Day's Range | 6.08 - 6.85 |
| 52 Week Range | 5.11 - 17.84 |
| Volume | 65,622 |
| Avg. Volume | 99,046 |
| Market Cap | 139.114M |
| Beta (5Y Monthly) | 2.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.26 |
| Earnings Date | Mar 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire
Pulse Biosciences Grants Equity Incentive Awards to New Employees
PULSE BIOSCIENCES GRANTS EQUITY INCENTIVE AWARDS TO NEW EMPLOYEES
- Business Wire
Pulse Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the fourth quarter and full year ended December 31, 2019.
- ACCESSWIRE
Pulse Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Pulse Biosciences, Inc. (NASDAQ:PLSE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 ...
- Business Wire
Pulse Biosciences Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 16, 2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the fourth quarter and full year 2019 after market close on Monday, March 16, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.
- Benzinga
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- Simply Wall St.
What You Must Know About Pulse Biosciences, Inc.'s (NASDAQ:PLSE) Beta Value
If you're interested in Pulse Biosciences, Inc. (NASDAQ:PLSE), then you might want to consider its beta (a measure of...
- Zacks
Pulse Biosciences Sees Hammer Chart Pattern: Time to Buy?
Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- Simply Wall St.
Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Could Pulse Biosciences, Inc.'s (NASDAQ:PLSE) Investor Composition Influence The Stock Price?
Every investor in Pulse Biosciences, Inc. (NASDAQ:PLSE) should be aware of the most powerful shareholder groups...
- Motley Fool
Pulse Biosciences, Inc Common Stock (PLSE) Q2 2019 Earnings Call Transcript
PLSE earnings call for the period ending June 30, 2019.
- Simply Wall St.
Is Pulse Biosciences's (NASDAQ:PLSE) 189% Share Price Increase Well Justified?
Pulse Biosciences, Inc. (NASDAQ:PLSE) shareholders might understandably be very concerned that the share price has...
- Benzinga
The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...
- Motley Fool
Pulse Biosciences, Inc. (PLSE) Q1 2019 Earnings Call Transcript
PLSE earnings call for the period ending March 31, 2019.
- Motley Fool
Pulse Biosciences, Inc. (PLSE) Q4 2018 Earnings Conference Call Transcript
PLSE earnings call for the period ending December 31, 2018.
- Simply Wall St.
How Many Insiders Bought Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- GlobeNewswire
Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire
Report: Developing Opportunities within Pulse Biosciences, Baxter International, FirstEnergy, Affiliated Managers Group, Baidu, and Shopify — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.
What Kind Of Risk Should You Expect For Pulse Biosciences Inc (NASDAQ:PLSE)?
Anyone researching Pulse Biosciences Inc (NASDAQ:PLSE) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/what-kind-of-risk-should-you-expect-for-pulse-biosciences-inc-nasdaqplse/">Read More...</a></div>
- ACCESSWIRE
Kaskela Law LLC Announces Investigation of Pulse Biosciences, Inc. on Behalf of Stockholders
RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) on behalf of the Company's stockholders. ...
- Motley Fool
Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today
Learn which companies rose on better business conditions in their industry.
- Benzinga
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Financial Select Sector SPDR Fund (NYSE: XLF ) stock ...
- Simply Wall St.
Is Pulse Biosciences Inc’s (NASDAQ:PLSE) CEO Incentives Align With Yours?
Darrin Uecker is the CEO of Pulse Biosciences Inc (NASDAQ:PLSE), which has recently grown to a market capitalization of US$266.53M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...
